Spero Therapeutics (SPRO) PT Slashed to $5 at Cantor Fitzgerald, Analyst Maintains "Overweight" Rating
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen lowered the price target on Spero Therapeutics (NASDAQ: SPRO) to $5.00 (from $27.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
